Can Biogen Dethrone Baxter in Hemophilia?

Biogen (BIIB) is launching its first drugs for the treatment of hemophilia this year, challenging Baxter's (BAX) long-held dominance.

Apr 25, 2014 at 6:30PM

Drugmakers like Biogen (NASDAQ:BIIB) are enjoying a new wave of success as they usher next-generation therapies to market that are displacing prior treatments.

Gilead has de-throned injectible drugs as the standard of care with a faster and better working oral drug, Sovaldi. Johnson & Johnson's Xarelto is casting aside warfarin's decades-long dominance as an anticoagulant in postoperative and cardiovascular patients. And in multiple sclerosis, Novartis, Sanofi, and Biogen are grabbing market share away from prior generation infusion therapies with new, oral drugs.

Biogen thinks it can be equally disruptive in treating hemophilia patients. Those patients have been treated with recombinant drug therapy for years that require two to three infusions weekly. By developing a longer-lasting alternative, Biogen hopes it can capture market share away from industry leader Baxter (NYSE:BAX), which commands more than 35% of the market.

BIIB Chart

BIIB data by YCharts

Improving treatment
Of course, Baxter isn't about to just hand over its market share leading position in the hemophilia market. It's worked too hard to build that product line into a multi-billion dollar franchise led by its top selling Advate.

But Biogen's most recently approved drug, Alprolix, and a likely approval later this year for Eloctate, could be one of the most significant advances in hemophilia treatment in years. That's because these drugs work longer, and are easier to adhere to, than prior generation therapies like Advate.

For example, Alprolix is approved as a treatment for hemophilia B. Because the drug works longer than existing therapies, it's more convenient to use, and offers fewer chances for patients to forget taking their medication as prescribed. Similarly, Biogen has formulated Eloctate, a treatment for hemophilia A that works longer, too.

How big is the opportunity?
Industry analysts project that spending on hemophilia drugs will grow from $8.5 billion in 2011 to $11.4 billion in 2016. The lion's share of that market is in hemophilia A, the most common version of hemophilia, affecting about 400,000 worldwide.

Currently, Baxter is the market-share leader in hemophilia A treatment thanks to Advate, a recombinant factor VIII replacement drug delivered two to three times a week by infusion. Advate's sales should total nearly $2 billion this year.

Others competing successfully in hemophilia A include Bayer and Pfizer (NYSE:PFE). Bayer makes about $2 billion a year from Kogenate, and Pfizer's Refacto/Xyntha had $169 million in sales during the fourth quarter.

While Biogen hasn't won FDA approval for its twice-a-week hemophilia A drug, Eloctate, it does expect an FDA decision this year. If approved, Eloctate will offer patients an alternative with a half-life 1.5 times longer than other existing hemophilia A drugs. Additionally, in trials, patients reported that they suffered a median six bleeding episodes in the prior year while on prior generation therapies, and no bleeding episodes while on Eloctate for three-months.

While Biogen awaits the FDA's decision on Eloctate, it will be rolling out Alprolix, its hemophilia B drug that got the FDA greenlight in March.

Hemophilia B is rarer than hemophilia A, affecting just 80,000 globally. But it's still an important market that is expected to grow from $1.2 billion to $1.8 billion by 2016 as more people are diagnosed. Currently, less than a third of those with hemophilia B have been diagnosed and are receiving treatment and, like type-A patients, type-B patients receive infusion two to three times weekly.

Pfizer is the market share leader in hemophilia B treatment thanks to its Benefix, which has been on the market since 1997. Pfizer's Benefix sales are north of $800 million a year, and its sales grew 8% year over year to $213 million in the fourth quarter.

Biogen hopes Alprolix can carve away sales from Pfizer and Baxter, given the drug can be taken once every week or 10 days -- a significant improvement over existing therapies like Baxter's twice-weekly Rixubus, which won FDA approval last June. In hopes of convincing doctors and patients to switch to Alprolix, Biogen has priced the drug in line with competitors' existing cost of roughly $300,000 per year.

Fool-worthy final thoughts
Biogen will have to overcome a handful of challenges. Hemophilia is a new market for Biogen, and Baxter, Bayer, and Pfizer are deeply entrenched with doctors worldwide. Biogen will have to also overcome the challenge of a historically slow rate of therapy switching among hemophilia patients.

Typically, patients starting on one therapy remain on that therapy. That means Biogen will need to convince doctors and patients that Alprolix and Eloctate are truly better. If it can't convince patients to switch, growth will be slower, and driven by newly diagnosed patients instead. Regardless, the opportunity has some analysts expecting that Biogen's hemophilia drugs could eventually generate more than $1 billion a year in sales, giving investors one more reason to consider this exciting biotech.

6 stock picks poised for incredible growth
They said it couldn't be done. But David Gardner has proved them wrong time, and time, and time again with stock returns like 926%, 2,239%, and 4,371%. In fact, just recently, one of his favorite stocks became a 100-bagger. And he's ready to do it again. You can uncover his scientific approach to crushing the market and his carefully chosen six picks for ultimate growth instantly, because he's making this premium report free for you today. Click here now for access.

Todd Campbell is long Gilead. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may or may not have positions in the companies mentioned. Todd owns Gundalow Advisors, LLC. Gundalow's clients do not have positions in the companies mentioned. The Motley Fool recommends Baxter International, Gilead Sciences, and Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.


Compare Brokers